BB Biotech (BBZAD) Stock Overview
An equity fund launched and managed by Bellevue Asset Management AG. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
BBZAD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
BB Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 51.85 |
| 52 Week High | CHF 50.10 |
| 52 Week Low | CHF 32.80 |
| Beta | 0.65 |
| 1 Month Change | 9.91% |
| 3 Month Change | 2.47% |
| 1 Year Change | 49.64% |
| 3 Year Change | 26.46% |
| 5 Year Change | -27.61% |
| Change since IPO | 312.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| BBZAD | GB Capital Markets | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | 1.0% |
| 1Y | 49.6% | -8.5% | 17.2% |
Return vs Industry: BBZAD exceeded the UK Capital Markets industry which returned -6.7% over the past year.
Return vs Market: BBZAD exceeded the UK Market which returned 17.3% over the past year.
Price Volatility
| BBZAD volatility | |
|---|---|
| BBZAD Average Weekly Movement | 3.2% |
| Capital Markets Industry Average Movement | 3.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: BBZAD has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine BBZAD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 10 | n/a | www.bbbiotech.ch/en/bb-biotech/ |
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology.
BB Biotech AG Fundamentals Summary
| BBZAD fundamental statistics | |
|---|---|
| Market cap | €2.96b |
| Earnings (TTM) | €864.25m |
| Revenue (TTM) | €668.35m |
Is BBZAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBZAD income statement (TTM) | |
|---|---|
| Revenue | CHF 616.88m |
| Cost of Revenue | CHF 0 |
| Gross Profit | CHF 616.88m |
| Other Expenses | -CHF 180.81m |
| Earnings | CHF 797.69m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 24, 2026
| Earnings per share (EPS) | 14.46 |
| Gross Margin | 100.00% |
| Net Profit Margin | 129.31% |
| Debt/Equity Ratio | 0% |
How did BBZAD perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/17 16:53 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BB Biotech AG is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rene Rückert | Baader Helvea Equity Research |
| Thomas Meyer | Baader Helvea Equity Research |
| Falko Friedrichs | Deutsche Bank |